Connecting the dots between phage pharmacokinetics, pharmacodynamics and immune interactions

Bacteriophage therapy is re-emerging as a promising strategy against multidrug-resistant bacterial infections, yet its clinical translation remains constrained by limited understanding of phage pharmacology and interactions within the human body. Unlike conventional antimicrobials, phages are self-amplifying biologically active particles that can interact with the immune system, such interactions can result in synergistic or antagonistic effects on immune function, leading to variable, unpredictable, and sometimes conflicting therapeutic outcomes. This review synthesizes the current knowledge based on in vivo findings related to phage pharmacokinetics and pharmacodynamics, especially regarding routes of administration, biodistribution, penetration through difficult-to-reach tissues, clearance pathways, and bacterial host effect. We further examine the current evidence for complex interplay between phages and mammalian immune system, including innate clearance, antibody-mediated neutralization, and the capacity of phages to induce immunological memory and immune tolerance. Current evidence indicates that the route and dose of phage administration can bias outcomes toward either tolerance or a robust neutralizing response, with important implications for repeated or prolonged therapy. Collectively, these insights emphasize the multifaceted aspects of phage therapy, which is not a straightforward therapeutic option, but inherently immunological and requires careful consideration of many factors prior to safe clinical application. Advancing the field toward rational, patient-specific application will require systematic human-based studies on pharmacokinetics and pharmacodynamics, longitudinal immune profiling, and rigorously designed clinical trials that directly link route, dose, formulation, and immune responses to reproducible clinical outcomes.